Paper22580997
Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.
Benhamou Y and 31 others. Haematologica, 2012. Cited by 130 papers, by iCite.
Cite this record
ConductScience Library. Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Papers, record 22580997. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22580997
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| ADAM Proteins | Major topic |
| Models, Statistical | Major topic |
| Purpura, Thrombocytopenic, Idiopathic | Major topic |
| ADAMTS13 Protein | |
| Adult | |
| Aged | |
| Cohort Studies | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Prognosis | |
| ROC Curve | |
| Registries | |
| Reproducibility of Results |
Source PubMed
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18028268 | Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. | Transfusion | 2008 | https://conductscience.org/library/papers/18028268 | PubMed |
| 2 | 7632812 | Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. | Ann Hematol | 1995 | https://conductscience.org/library/papers/7632812 | PubMed |
| 3 | 16371021 | Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. | Br J Haematol | 2006 | https://conductscience.org/library/papers/16371021 | PubMed |
| 4 | 20955397 | Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. | Br J Haematol | 2010 | https://conductscience.org/library/papers/20955397 | PubMed |
| 5 | 14982878 | Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. | Blood | 2004 | https://conductscience.org/library/papers/14982878 | PubMed |
| 6 | 19180136 | TTP/HUS: observational studies generate hypotheses that lead to randomized controlled trials. | Kidney Int Suppl | 2009 | https://conductscience.org/library/papers/19180136 | PubMed |
| 7 | 21657946 | Investigational drugs in thrombotic thrombocytopenic purpura. | Expert Opin Investig Drugs | 2011 | https://conductscience.org/library/papers/21657946 | PubMed |
| 8 | 17164349 | Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. | Blood | 2007 | https://conductscience.org/library/papers/17164349 | PubMed |
| 9 | 19586943 | Vascular endothelial ageing, heartbeat after heartbeat. | Cardiovasc Res | 2009 | https://conductscience.org/library/papers/19586943 | PubMed |
| 10 | 18574040 | Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. | Blood | 2008 | https://conductscience.org/library/papers/18574040 | PubMed |
| 11 | 19350168 | [Thrombotic thrombocytopenic purpura: experience in 18 cases and literature review]. | Rev Med Chil | 2008 | https://conductscience.org/library/papers/19350168 | PubMed |
| 12 | 3203132 | Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. | Biometrics | 1988 | https://conductscience.org/library/papers/3203132 | PubMed |
| 13 | 3661582 | High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. | Am J Med | 1987 | https://conductscience.org/library/papers/3661582 | PubMed |
| 14 | 16574680 | Acute myocardial infarction in thrombotic microangiopathies--clinical characteristics, risk factors and outcome. | Nephrol Dial Transplant | 2006 | https://conductscience.org/library/papers/16574680 | PubMed |
| 15 | 16398654 | Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange. | Br J Haematol | 2006 | https://conductscience.org/library/papers/16398654 | PubMed |
| 16 | 20032506 | Survival and relapse in patients with thrombotic thrombocytopenic purpura. | Blood | 2010 | https://conductscience.org/library/papers/20032506 | PubMed |
| 17 | 18048471 | Arterial aging: pathophysiological principles. | Vasc Med | 2007 | https://conductscience.org/library/papers/18048471 | PubMed |
| 18 | 10741917 | Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases. | Ann Hematol | 2000 | https://conductscience.org/library/papers/10741917 | PubMed |
| 19 | 20378566 | Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. | Haematologica | 2010 | https://conductscience.org/library/papers/20378566 | PubMed |
| 20 | 9590492 | Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. | J Clin Apher | 1998 | https://conductscience.org/library/papers/9590492 | PubMed |
Cited by68
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 130 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42812790 | Current standards and novel concepts in thrombotic thrombocytopenic purpura. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42812790 | PubMed |
| 42747330 | Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue. | J Clin Apher | 2026 | https://conductscience.org/library/papers/42747330 | PubMed |
| 42566758 | Mortality prediction in immune TTP remains challenging despite artificial intelligence advances. | Blood Adv | 2026 | https://conductscience.org/library/papers/42566758 | PubMed |
| 42527695 | Acute neurologic clinical manifestations and outcomes in children with thrombotic microangiopathies in paediatric intensive care units. | Eur J Pediatr | 2026 | https://conductscience.org/library/papers/42527695 | PubMed |
| 42431609 | Unbiased plasma proteomics reveals hemolysis during ADAMTS13 relapse in patients with immune TTP. | Blood Adv | 2026 | https://conductscience.org/library/papers/42431609 | PubMed |
| 42145720 | The landscape of ADAMTS13-related tests in thrombotic thrombocytopenic purpura: a review. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42145720 | PubMed |
| 41991316 | [Caplacizumab combined with therapeutic plasma exchange, glucocorticoids, and rituximab for refractory thrombotic thrombocytopenic purpura: a case report and literature review]. | Zhonghua Xue Ye Xue Za Zhi | 2026 | https://conductscience.org/library/papers/41991316 | PubMed |
| 41940237 | Epidemiology, therapy, and outcome of immune-mediated thrombotic thrombocytopenic purpura at population level in Germany. | Res Pract Thromb Haemost | 2026 | https://conductscience.org/library/papers/41940237 | PubMed |
| 41917368 | Treating Immune-Mediated Thrombotic Thrombocytopenic Purpura with Caplacizumab. | Methods Mol Biol | 2026 | https://conductscience.org/library/papers/41917368 | PubMed |
| 41917366 | Treating Immune Thrombotic Thrombocytopenic Purpura with Therapeutic Plasma Exchange. | Methods Mol Biol | 2026 | https://conductscience.org/library/papers/41917366 | PubMed |
| 41613148 | Experience in emergency management of first-episode immune thrombotic thrombocytopenic purpura over the past 21 years: a single-center retrospective study. | Front Immunol | 2025 | https://conductscience.org/library/papers/41613148 | PubMed |
| 41001423 | Intravascular Lymphoma Presenting as Multiple Endocrine Failure, Transforming Into the Hemophagocytic Variant, and Relapsing as a Thrombotic Microangiopathy. | Case Rep Hematol | 2025 | https://conductscience.org/library/papers/41001423 | PubMed |
| 40765928 | Genetic variants contribute to modulation of renal function in patients with immune thrombotic thrombocytopenic purpura. | Blood Vessel Thromb Hemost | 2024 | https://conductscience.org/library/papers/40765928 | PubMed |
| 40662571 | Anti-ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune-Mediated TTP. | Am J Hematol | 2025 | https://conductscience.org/library/papers/40662571 | PubMed |
| 40235949 | Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project). | EClinicalMedicine | 2025 | https://conductscience.org/library/papers/40235949 | PubMed |
| 39534187 | Systematic Review of Individual Patient Data COVID-19 Infection and Vaccination-Associated Thrombotic Microangiopathy. | Kidney Int Rep | 2024 | https://conductscience.org/library/papers/39534187 | PubMed |
| 39221451 | Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura. | Res Pract Thromb Haemost | 2024 | https://conductscience.org/library/papers/39221451 | PubMed |
| 39209728 | Clinical, biological, prognostic characteristics of patients with immune-mediated thrombotic thrombocytopenic purpura and Sjögren's disease. | RMD Open | 2024 | https://conductscience.org/library/papers/39209728 | PubMed |
| 39095866 | Frontline use of rituximab may prevent ADAMTS13 inhibitor boosting during caplacizumab treatment in patients with iTTP: post hoc analysis of a phase 2/3 study in Japan. | Thromb J | 2024 | https://conductscience.org/library/papers/39095866 | PubMed |
| 38651093 | A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura. | Res Pract Thromb Haemost | 2024 | https://conductscience.org/library/papers/38651093 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ADAMTS13 | 11093 | PubTator's text mining | https://conductscience.org/library/genes/11093 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22580997
GET https://conductscience.org/api/papers/v1/22580997/authors?page=2